Education
About Us
Working with TipRanks
Follow Us
Esperion Therapeutics (ESPR)
NASDAQ:ESPR
ESPR Stock Chart & Stats
$2.55
-$0.02(-0.92%)
At close: 4:00 PM EST
$2.55
-$0.02(-0.92%)
Day’s Range― - ―
52-Week Range$0.69 - $4.18
Previous CloseN/A
Volume1.55M
Average Volume (3M)4.41M
Market Cap
$654.87M
Enterprise Value$910.32M
Total Cash (Recent Filing)$167.85M
Total Debt (Recent Filing)$548.00M
Price to Earnings (P/E)―
Beta2.48
Next Earnings
May 12, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.22
Shares Outstanding256,810,500
10 Day Avg. Volume6,128,068
30 Day Avg. Volume4,412,041
Financial Highlights & Ratios
PEG Ratio0.56
Price to Book (P/B)-2.55
Price to Sales (P/S)1.91
P/FCF Ratio-59.60
Enterprise Value/Market Cap1.39
Enterprise Value/Revenue2.26
Enterprise Value/Gross Profit3.50
Enterprise Value/Ebitda14.50
Forecast
1Y Price Target
$7.30Price Target Upside186.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)0.07
Revenue Forecast (FY)$410.58M
Bulls Say, Bears Say
Bulls Say
Commercial And International ExpansionExpanded U.S. sales execution and planned market entry into countries such as Europe and Japan could broaden uptake and support international revenue growth for the bempedoic acid franchise as access improves.
Guideline EndorsementGuideline endorsements position bempedoic acid as a recommended non‑statin therapy, increasing clinician likelihood to prescribe Nexletol and Nexlizet for patients who need additional cholesterol lowering.
Product Portfolio DiversificationAcquisitions that add Enbumyst and Corstasis bring new commercial therapies and pipeline assets, creating multiple revenue avenues beyond cholesterol treatments and supporting a transition to a multiproduct cardiometabolic company.
Bears Say
Competitive PressureEmerging oral and injectable cholesterol drugs and strong Phase 3 results from competitors may reduce differentiation for bempedoic acid and limit its market share expansion.
Cost And Payer BarriersHigh out-of-pocket costs and the branded status of the drug could restrict patient access and slow adoption even with favorable guideline positioning, pressuring sales growth.
Limited Commercial SynergiesThe hospital and clinic focus for the new nasal diuretic differs from outpatient cholesterol prescribing, reducing expected sales-force overlap and making the acquisition's contribution to sales uncertain.
Esperion News
ESPR FAQ
What was Esperion Therapeutics’s price range in the past 12 months?
Esperion Therapeutics lowest stock price was $0.69 and its highest was $4.17 in the past 12 months.
What is Esperion Therapeutics’s market cap?
Esperion Therapeutics’s market cap is $654.87M.
When is Esperion Therapeutics’s upcoming earnings report date?
Esperion Therapeutics’s upcoming earnings report date is May 12, 2026 which is in 50 days.
How were Esperion Therapeutics’s earnings last quarter?
Esperion Therapeutics released its earnings results on Mar 10, 2026. The company reported $0.22 earnings per share for the quarter, missing the consensus estimate of $0.243 by -$0.023.
Is Esperion Therapeutics overvalued?
According to Wall Street analysts Esperion Therapeutics’s price is currently Undervalued.
Does Esperion Therapeutics pay dividends?
Esperion Therapeutics does not currently pay dividends.
What is Esperion Therapeutics’s EPS estimate?
Esperion Therapeutics’s EPS estimate is -0.02.
How many shares outstanding does Esperion Therapeutics have?
Esperion Therapeutics has 256,810,500 shares outstanding.
What happened to Esperion Therapeutics’s price movement after its last earnings report?
Esperion Therapeutics reported an EPS of $0.22 in its last earnings report, missing expectations of $0.243. Following the earnings report the stock price went down -11.184%.
Which hedge fund is a major shareholder of Esperion Therapeutics?
Currently, no hedge funds are holding shares in ESPR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Esperion Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.30 (186.27% Upside)
$7.30 (186.27% Upside)
Blogger Sentiment
Neutral
ESPR Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 968.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $106.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.1%
Last 30 Days ▲ 3.9%
Last 30 Days ▲ 3.9%
News Sentiment
Very Bearish
Bullish news 19%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
57.40%
12-Months-Change
Fundamentals
Return on Equity
5.62%
Trailing 12-Months
Asset Growth
155.90%
Trailing 12-Months
Company Description
Esperion Therapeutics
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
ESPR Company Deck
ESPR Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected strong revenue growth, successful strategic initiatives, and international expansion. However, increased operating expenses and onetime financial impacts were noted as challenges. Overall, the highlights of growth and strategic progress outweigh the lowlights.View all ESPR earnings summariesESPR Stock 12 Month Forecast
Average Price Target
$7.30
▲(186.27% Upside)
Technical Analysis
Ownership Overview
1.86% Insiders
12.24% Mutual Funds
19.22% Other Institutional Investors
55.25% Public Companies and
Individual Investors